MAP2K7 and hairy cell leukemia: Superior in terms of drug tolerability when compared with chemo(immuno)therapy, BRAF- and MEK-inhibitors already serve as a valuable therapeutic alternative for HCL patients not qualifying for standard chemo(immuno)therapy, i.e., due to active infections, comorbidities and/or advanced age [21].